Skip to main content

Table 6 Comparison of CHEK2 mutation frequency in patients with selected tumours and in the control group

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Location or type of tumour

Number of tested

Number of mutation carriers (frequency), results of statistical analysis*

  

IVS2+1G>A

1100delC

1100delC or IVS2+1G>A

I157T

Bladder

172

1 (0.6%)

 

1 (0.6%)

12 (7.0%)

  

OR = 1.2

0

OR = 0.8

OR = 1.5

  

p = 0.7

 

p = 0.8

p = 0.3

Kidney

264

0

2 (0.8%)

2 (0.8%)

26 (9.8%)

   

OR = 2.7

OR = 1.0

OR = 2.1

   

p = 0.5

p = 0.8

p = 0.0006

Larynx

245

0

0

0

10 (4.1%)

OR = 0.8

p = 0.7

Lung

272

0

0

0

7 (2.6%)

OR = 0.5

p = 0.1

Melanoma

129

2 (1.5%)

OR = 3.3

p = 0.3

1 (0.8%)

OR = 3.1

p = 0.8

3 (2.3%)

OR = 3.2

p = 0.1

6 (4.6%)

OR = 1.0

p = 0.9

Ovary

292

0

0

0

14 (4.8%)

OR = 1.0

p = 0.9

Stomach

241

4 (1.7%)

OR = 3.5

p = 0.05

0

4 (2.1%)

OR = 2.3

p = 0.2

13 (5.4%)

OR = 1.1

p = 0.8

NHL

120

1 (0.8%)

OR = 1.8

p = 0.9

0

1 (0.8%)

OR = 1.1

p = 0.7

11 (9.2%)

OR = 2.0

p = 0.05

Pancreas

93

0

0

0

6 (6.4%)

OR = 1.4

p = 0.6

Thyroid

173

5 (2.9%)

OR = 6.2

p = 0.0003

1 (0.6%)

OR = 2.3

p = 0.9

6 (3.5%)

OR = 4.9

p = 0.0006

15 (8.7%)

OR = 1.9

p = 0.04

Controls

4000

19 (0.475%)

10 (0.25%)

29 (0.725%)

193 (4.825%)

  1. *comparison of CHEK2 mutation frequency in patients with specific tumour type to that of control group
  2. NHL – non-Hodgkin lymphoma; OR – odds ratio; p – p-value